C2T2 News

	Investigators match novel cancer mutations with potential therapies Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients. They identified a novel gene mutation that develops in the tumors, and then found a different cancer drug that appears to treat the newly identified mutation. The […] Monday, August 7th, 2017
	Arteaga to direct UT Southwestern cancer center Carlos L. Arteaga, M.D. Thursday, July 13th, 2017
	V Foundation grants bolster cancer initiatives Two Vanderbilt-Ingram Cancer Center (VICC) investigators have earned grant awards from The V Foundation for Cancer Research, continuing the foundation’s support for innovative cancer research initiatives at VICC. Raymond Blind, Ph.D. Thursday, November 17th, 2016
	Precision medicine already changing cancer treatment strategies The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. “Nationwide we’re seeing great promise with this approach […] Thursday, May 26th, 2016
	VICC investigators in spotlight at AACR conference A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures. Carlos L. Arteaga, M. Thursday, May 19th, 2016
	Public invited to learn about VICC precision cancer medicine Leading cancer investigators from Vanderbilt-Ingram Cancer Center will unveil the latest in cancer research during an upcoming community event. “Precision Medicine in Cancer: At the Crossroads of Research and Treatment for Patients” will be held Tuesday, May 10, from 5: Friday, April 29th, 2016
	Study explores how some breast cancers resist treatment A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies. The new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators has identified gene alterations […] Thursday, April 21st, 2016
	VICC’s Balko named a Susan G. Komen ‘Pink Tie Guy’ Justin Balko, Pharm.D., Ph. Thursday, December 10th, 2015